GlassScriptPhysician profile
Srinivasan Ganesan
NPI 1124222526
$3,089.18
in general payments reported to CMS, 2019-2025
27 companies · $666 in 2025
The $666 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $384 · 2020: $145 · 2021: $368 · 2022: $295 · 2023: $533 · 2024: $698 · 2025: $666.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,866 · Education: $31.07.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,866.19 |
| Education | $31.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $800.42 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $442.02 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Braintree Laboratories, INC. | $274.32 | 2019-2025 | Sutab, Suflave |
| Ardelyx, INC. | $129.88 | 2024-2025 | Ibsrela |
| Lilly USA, LLC | $125.81 | 2024-2025 | Omvoh |
| Ironwood Pharmaceuticals, INC | $108.38 | 2019-2023 | Linzess |
| Qol Medical, LLC | $108.14 | 2023-2025 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $105.76 | 2020-2025 | |
| Pfizer INC. | $102.38 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $95.03 | 2019-2022 | |
| Medtronic, INC. | $92.42 | 2024-2025 | Interstim |
| Redhill Biopharma INC. | $81.23 | 2020-2021 | |
| Phathom Pharmaceuticals, INC. | $74.39 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $74.28 | 2023-2025 | Tremfya, Simponi, Remicade |
| Merck Sharp & Dohme LLC | $71.33 | 2021-2023 | Dificid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $67.47 | 2021-2023 | Zeposia |
| Intercept Pharmaceuticals, INC. | $64.44 | 2019-2022 | |
| Mauna Kea Technologies, INC. | $64.02 | 2023-2025 | |
| Madrigal Pharmaceuticals | $48.64 | 2024-2025 | Resmetirom, Rezdiffra |
| Regeneron Healthcare Solutions, INC. | $22.68 | 2022 | |
| Genzyme Corporation | $22.57 | 2023 | |
| Aimmune Therapeutics, INC. | $21.89 | 2025 | Zenpep |
| Ipsen Biopharmaceuticals, INC | $21.69 | 2025 | Iqirvo |
| Alfasigma USA, INC. | $21.03 | 2020 | |
| Celltrion USA INC. | $18.23 | 2024 | Zymfentra |
| Novo Nordisk INC | $18.17 | 2025 | Wegovy |
| Allergan, INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivasan Ganesan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.